Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.
You may also be interested in...
Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
JAKs Are Better? Oral Inhibitors Could Beat Injected Biologics In RA
Buzz over data from trials with Janus-associated kinase inhibitors at the American College of Rheumatology meeting is heating up the debate over whether the class will ultimately beat injected biologics in rheumatoid arthritis